Abstract
Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carryNPM1mutations. The classicNPM1type A mutation occurs in exon 12, which accounts for 75–80% of adult patients withNPM1-mutated AML. It produces an additional leucine and valine-rich nuclear export signal (NES) at the C-terminus, and causes aberrant cytoplasmic dislocation of NPM1 protein. Notably, emerging evidence indicates that besides the classic type A mutation, rare mutants occurring in other exons may also lead to the imbalance of the nucleocytoplasmic shuttle of NPM1. Identification of novel non-type A mutants is crucial for the diagnosis, prognosis, risk stratification and disease monitoring of potential target populations. Here we reported a novelNPM1mutation in exon 5 identified from a de novo AML patient. Similar to the classic type A mutation, the exon 5 mutation had the NPM1 mutant bound to exportin-1 and directed the mutant into the cytoplasm by generating an additional NES sequence, resulting in aberrant cytoplasmic dislocation of NPM1 protein, which could be reversed by exportin-1 inhibitor leptomycin B. Our findings strongly support that besides the exon 12 mutation, the exon 5 mutant is anotherNPM1“born to be exported” mutant critical for leukemogenesis. Therefore, similar to the classic type A mutation, the identification of our novelNPM1mutation is beneficial for clinical laboratory diagnosis, genetic risk assessment and MRD monitoring.
Funding Information
  • 2023 Science and Technology Innovation Plan of Shanghai Science and Technology Commission (23141902700)
  • the Fundamental Research Funds for the Central Universities (226-2022-00003)
  • Natural Science Foundation of Zhejiang Province, China (Y23H080018)
  • Key Research and Development Program of Zhejiang Province, China (2022C03005)

This publication has 13 references indexed in Scilit: